Drug Details

General Information of the Drug (ID: DR3313)
Name
Isoniazid
Synonyms
isoniazid; 54-85-3; Isonicotinic acid hydrazide; Isonicotinohydrazide; pyridine-4-carbohydrazide; Isoniazide; Nydrazid; Rimifon; Isonicotinic hydrazide; Laniazid; Isonicotinylhydrazine; Andrazide; Cotinazin; Dinacrin; Hydrazid; Neoteben; Nicizina; Nicotibina; Nicozide; Pycazide; Tubazide; Ditubin; Iscotin; Isolyn; Isonex; Mybasan; Niconyl; Hyzyd; Isonicotinhydrazid; Antimicina; Atcotibine; Chemiazid; Hidranizil; Hidrasonil; Hydrazide; Isobicina; Isocidene; Isohydrazide; Isonicotan; Isonicotil; Isonidrin; Isonikazid; Isonindon; Isonizide; Isotebezid; Neumandin; Pyricidin; Pyrizidin; Stanozide; Armazid; Armazide; Cemidon; Chemidon; Defonin; Diforin; Ebidene; Ertuban; Eutizon; Fimalene; Hidrulta; Hycozid; Idrazil; Isidrina; Ismazide; Isocotin; Isonerit; Isonicid; Isonico; Isonide; Isonilex; Isonirit; Isoniton; Isozide; Niadrin; Nicetal; Nidaton; Nidrazid; Nikozid; Nitadon; Nyscozid; Pelazid; Raumanon; Retozide; Rimicid; Rimitsid; Tubazid; Azuren; Cedin; Eralon; Evalon; Hidrun; Inizid; Isocid; Isonin; Isozyd; Neoxin; Nevin; Niplen; Antituberkulosum; Inah; Ido-tebin; 4-Pyridinecarboxylic acid, hydrazide; Bacillin; Isoniacid; Isotinyl; Nicazide; Nicotibine; Nicotisan; Phthisen; Pyreazid; Rimiphone; Tubilysin; Isotebe; Percin; Razide; Tyvid; Isoniazid SA; Neo-Tizide; GINK; Armacide; Cortinazine; Cotinizin; Isonicazide; Isotamine; Robisellin; Sauterazid; Teebaconin; Tibinide; Unicozyde; Vazadrine; Zonazide; Dibutin; Hyozid; Isonicotinoyl hydrazide; Tebecid; Tekazin; Tubeco; Tubicon; Tubomel; Vederon; Zinadon; Preparation 6424; Isonicotinyl hydrazide; TB-Razide; Sanohidrazina; Tisiodrazida; Laniozid; Niteban; Pyridicin; Robiselin; Roxifen; Sauterzid; Tebenic; Tebexin; Tebilon; Tibazide; Tibison; Tibivis; Tibizide; Tibusan; Tuberian; Tubizid; Unicocyde; Tebos; Tisin; Tizide; 4-Pyridinecarboxylic acid hydrazide; Dow-Isoniazid; FSR 3; TB-Vis; Inh-Burgthal; INH; TB-Phlogin; Zidafimia; Isokin; Nitebannsc 9659; In-73; RU-EF-Tb; isonicotinoylhydrazide; Isonicotinoylhydrazine; 4-Pyridinecarbonylhydrazine; BP 5015; FSR-3; Isonicotinsaeurehydrazid; 4-(Hydrazinocarbonyl)pyridine; 4-pyridinecarbohydrazide; 4-Pyridylcarbonylhydrazide; NSC 9659; MFCD00006426; HIA; RP-5015; UNII-V83O1VOZ8L; pyridine-4-carboxylic acid hydrazide; Isonicotinylhydrazide; L 1945; 5015 RP; CHEBI:6030; isonicotinate hydrazide; 5015 R.P.; CHEMBL64; V83O1VOZ8L; MLS000069444; Isozid; NSC9659; Isoniazid-d4; NSC-9659; Cedin (Aerosol); CAS-54-85-3; bacillen; tebemid; tubercid; NCGC00016244-09; Continazine; Isoniazidum; Tubecotubercid; Abdizide; Anidrasona; Isoniazida; Isonizida; SMR000059082; Tibemid; Tibiazide; Fetefu; Hydra; DSSTox_CID_755; DSSTox_RID_75771; DSSTox_GSID_20755; LANIZID; 4-Pyridinecarboxylic hydrazide; Isonicotinic acid hydrazide, 99%; RY-EF-Tb; Isoniazidum [INN-Latin]; Isoniazida [INN-Spanish]; AZT + Isoniazid; FRS-3; Isoniazid(Tubizid); Laniazid (TN); CCRIS 351; Usaf cb-2; HSDB 1647; Isonicotinsaeurehydrazid [German]; INHd20; SR-01000003025; EINECS 200-214-6; RP 5015; Mayambutol; AI3-23936; I.A.I.; Idrazide dell'acido isonicotinico [Italian]; isoniazid (inh); Isoniazid/INH; Idrazide dell'acido isonicotinico; Isoniazid [USP:INN:BAN:JAN]; isonicotinhydrazide; Soniazid,(S); NIZ; Prestwick_578; Isoniazid (Tubizid); Rifater (Salt/Mix); Isonicotinic acid hydrazide (Isoniazid); Spectrum_000853; ACMC-209ljq; Opera_ID_454; isonicotinicacid hydrazide; isonicotinic acid hydrazid; Prestwick0_000161; Prestwick1_000161; Prestwick2_000161; Prestwick3_000161; Spectrum2_000107; Spectrum3_000472; Spectrum4_000022; Spectrum5_000876; I0138; WLN: T6NJ DVMZ; isonicotinic acid hydrazone; SCHEMBL228; Biomol-NT_000288; Epitope ID:141801; 4-Pyridylcarbonyl hydrazide; Oprea1_396155; BSPBio_000021; BSPBio_002204; KBioGR_000423; KBioSS_001333; MLS001055327; ARONIS25141; BIDD:GT0140; DivK1c_000070; SPECTRUM1500355; SPBio_000094; SPBio_001942; Isoniazid (JP17/USP/INN); BPBio1_000025; BPBio1_001322; SCHEMBL2998929; ZINC1590; component of Niadox (Salt/Mix); DTXSID8020755; HMS500D12; KBio1_000070; KBio2_001333; KBio2_003901; KBio2_006469; KBio3_001424; NINDS_000070; HMS1568B03; HMS1920H09; HMS2089I16; HMS2091N19; HMS2095B03; HMS2234G04; HMS3259E19; HMS3373O01; HMS3655L03; HMS3712B03; KUC109571N; Pharmakon1600-01500355; 4-pyridinecarbohydrazide(Isoniazid); BCP13791; HY-B0329; STR00210; [(4-Pyridinylcarbonyl)oxy]hydrazine; Anti-TNF monoclonal antibody & INH; Tox21_113640; Tox21_201367; Tox21_300193; ANW-32196; BBL008409; BDBM50336507; CCG-39710; NSC757078; s1937; SBB004195; STK086288; AKOS000119062; Isonicotinic acid hydrazide(Isoniazid); Tox21_113640_1; DB00951; KSC-27-048; MCULE-6324947959; NC00513; NSC-757078; PS-4129; IDI1_000070; UPCMLD0ENAT5791176:001; NCGC00016244-01; NCGC00016244-02; NCGC00016244-03; NCGC00016244-04; NCGC00016244-05; NCGC00016244-06; NCGC00016244-07; NCGC00016244-08; NCGC00016244-10; NCGC00016244-11; NCGC00016244-12; NCGC00016244-14; NCGC00016244-15; NCGC00022648-03; NCGC00022648-04; NCGC00022648-05; NCGC00022648-06; NCGC00022648-07; NCGC00254094-01; NCGC00258919-01; AK-46317; ST078858; SY010614; Isoniazid, Vetec(TM) reagent grade, 98%; SBI-0051419.P003; [NH-]NC(=[OH+])C1=CC=NC=C1; AB00052025; BB 0240534; FT-0627424; FT-0670476; SW196752-3; T7976; ISONICOTINIC ACID HYDRAZIDE(ISONIAZIDE); C07054; D00346; Isoniazid, analytical standard, >=99% (TLC); 10319-EP2272972A1; 10319-EP2272973A1; 10319-EP2274983A1; 10319-EP2275102A1; 10319-EP2275401A1; 10319-EP2277872A1; 10319-EP2280000A1; 10319-EP2280012A2; 10319-EP2281563A1; 10319-EP2289510A1; 10319-EP2289876A1; 10319-EP2295407A1; 10319-EP2295411A1; 10319-EP2295416A2; 10319-EP2295433A2; 10319-EP2298312A1; 10319-EP2298736A1; 10319-EP2298747A1; 10319-EP2298748A2; 10319-EP2301536A1; 10319-EP2301538A1; 10319-EP2301924A1; 10319-EP2305640A2; 10319-EP2305642A2; 10319-EP2305808A1; 10319-EP2308852A1; 10319-EP2311455A1; 10319-EP2311824A1; 10319-EP2311830A1; 10319-EP2314584A1; 10319-EP2316452A1; 10319-EP2316459A1; 10319-EP2380872A1; 40687-EP2298761A1; 40687-EP2311830A1; AB00052025-20; AB00052025-21; AB00052025_22; AB00052025_23; AB00052025_24; AB00052025_25; 101033-EP2272832A1; 101033-EP2272972A1; 101033-EP2272973A1; 101033-EP2277872A1; 101033-EP2295053A1; 101033-EP2298776A1; 101033-EP2301544A1; AE-641/02310003; Q423169; SR-01000003025-2; SR-01000003025-3; BRD-K87202646-001-26-8; Isoniazid, certified reference material, TraceCERT(R); Z58981801; F0391-0007; Isoniazid, European Pharmacopoeia (EP) Reference Standard; Isoniazid, United States Pharmacopeia (USP) Reference Standard; Isoniazid, Pharmaceutical??Secondary??Standard;??Certified??Reference??Material
    Click to Show/Hide
Molecular Type
Small molecule
Disease HIV-associated tuberculosis [ICD-11: 1C60] Approved [1]
Structure
Click to Download Mol
2D MOL

3D MOL

ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability
Bioavailability
80% of drug becomes completely available to its intended biological destination(s)
Clearance
The drug present in the plasma can be removed from the body at the rate of 7.4 mL/min/kg
Elimination
7% of drug is excreted from urine in the unchanged form
Half-life
The concentration or amount of drug in body reduced by one-half in 0.5 - 1.6 hours
Metabolism
The drug is metabolized via the hepatic
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 72.91702 micromolar/kg/day
Unbound Fraction
The unbound fraction of drug in plasma is 1%
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.82 L/kg
Water Solubility
The ability of drug to dissolve in water is measured as 153 mg/mL
    Click to Show/Hide
    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C6H7N3O
PubChem CID
3767
Canonical SMILES
C1=CN=CC=C1C(=O)NN
InChI
1S/C6H7N3O/c7-9-6(10)5-1-3-8-4-2-5/h1-4H,7H2,(H,9,10)
InChIKey
QRXWMOHMRWLFEY-UHFFFAOYSA-N
CAS Number
CAS 54-85-3
ChEBI ID
CHEBI:6030
TTD Drug ID
D09XQF
DrugBank ID
DB00951
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          Allium sativum      Allium sativum     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    In-vivo Model Clinical Trial
                    Experimental
                    Result(s)		 Garlic extracts or compounds have a good potential as antitubercular(s) drug if given as a supplement to ATT.
          Ferutinin      Ferula sinkiangensisK     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [3]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Experimental
                    Result(s)		 The combination of 1 with each antitubercular drug led to mutual enhancement of the antimycobacterial activity with isoniazid and ethionamide, while no such effect was observed with rifampin or streptomycin.
          Oleanolic acid      Olea europaea     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [4]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    In-vitro Model Vero CVCL_0059 Healthy Chlorocebus sabaeus
                    Experimental
                    Result(s)		 Oleanolic acid and combination displayed either a synergistic interaction or did not show any interaction against two drug-sensitive strains.
Target and Pathway
Target(s) Bacterial Fatty acid synthetase I (Bact inhA)  Molecule Info  [5]
References
Reference 1 Novel agents in the management of Mycobacterium tuberculosis disease. Curr Med Chem. 2007;14(18):2000-8.
Reference 2 Antitubercular activity of garlic (allium sativum) extract on combination with conventional antitubercular drugs in tubercular lymphadenitis. Indian J Clin Biochem. 1999 Jan;14(1):12-8.
Reference 3 Antimycobacterial activity of ferutinin alone and in combination with antitubercular drugs against a rapidly growing surrogate of Mycobacterium tuberculosis. Nat Prod Res. 2011 Jul;25(12):1142-9.
Reference 4 In vitro synergistic interactions of oleanolic acid in combination with isoniazid, rifampicin or ethambutol against Mycobacterium tuberculosis. J Med Microbiol. 2010 May;59(Pt 5):567-572.
Reference 5 Diversity in enoyl-acyl carrier protein reductases. Cell Mol Life Sci. 2009 May;66(9):1507-17.
 Download Picture         KEGG Link